

DRUG NAME: Leucovorin**SYNONYM(S):** calcium folinate, citrovorum factor,¹ folinic acid,² 5-formyl tetrahydrofolate²**COMMON TRADE NAME(S):** generic available, LEDERLE LEUCOVORIN®**CLASSIFICATION:** folic acid metabolite, noncytotoxic³*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Leucovorin is an active metabolite of folic acid and an essential coenzyme for nucleic acid synthesis.¹ Leucovorin can be used to selectively "rescue" cells from the adverse effects of methotrexate or to increase the efficacy of fluorouracil.

Methotrexate inhibits nucleic acid synthesis by blocking the activation of folic acid. Leucovorin is folic acid in its active (reduced) form, so it allows nucleic acid synthesis to proceed even in the presence of methotrexate. Leucovorin can also compete with methotrexate for the same transport processes into the cell.² Leucovorin is usually administered 24 hours after methotrexate so that it does not interfere with the therapeutic effect of methotrexate. Leucovorin can also be used in overdose situations; it should be administered as soon as possible.²

Fluorouracil inhibits nucleic acid synthesis by several mechanisms, including binding to thymidylate synthetase. A leucovorin metabolite (5-methyl-tetrahydrofolate [5-MTHF]) stabilizes the bond formed between a fluorouracil metabolite (fluorodeoxyuridine monophosphate) and thymidylate synthetase.⁴ This causes a decrease in intracellular levels of that enzyme and a resulting decrease in the production of thymidylate. In this way, leucovorin can enhance or modulate the activity of fluorouracil. Leucovorin is usually administered just prior to fluorouracil.

In Canada, leucovorin is available as a racemic mixture containing equal parts of d and l isomers (d,l-leucovorin); the biologically active isomer is the l isomer (l-leucovorin).^{2,5} In other parts of the world a pure l-leucovorin product is available e.g., in France (ELVORINE®) and in the UK (ISOVORIN®). Dosing for d,l-leucovorin is different than dosing for l-leucovorin.

PHARMACOKINETICS:

Oral Absorption	90% absorbed after oral ingestion ³ ; saturable at doses ⁴ >25 mg	
Distribution	all tissues ⁶	
	cross blood brain barrier?	readily ⁶
	volume of distribution	3.2 L/kg
	plasma protein binding	35-45%
Metabolism	rapidly and extensively converted to 5-MTHF in the intestine prior to absorption	
	active metabolite	5-MTHF
	inactive metabolite	yes
Excretion	rapidly excreted in the urine	
	urine	80-90%
	feces	5-8%
	terminal half life	leucovorin: 15 min 5-MTHF: 35-45 min
	clearance	3.9 mL/min/kg

Adapted from standard reference^{2,7} unless specified otherwise.

USES:**Primary uses:**

- *Leucovorin rescue after methotrexate
- *Enhance cytotoxicity of fluorouracil
- *Health Canada approved indication

Other uses:**SPECIAL PRECAUTIONS:****Caution:**

- Absorption is saturable; doses >25 mg should be given IV.⁴
- Doses >1000 mg/m² q6h are associated with cardiac arrhythmias resulting from hypercalcemia.⁸
- Intrathecal administration not recommended.²
- Increases the cytotoxicity and toxicity of fluorouracil.²

Carcinogenicity: no information found.

Mutagenicity: no information found.

Fertility: no problems have been documented.²

Pregnancy: FDA Pregnancy Category C⁹. Animal studies have shown fetal risks and there are no controlled studies in women or studies in women and animals are not available. Drug should be given only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding: Leucovorin enters breast milk; caution should be used when administering leucovorin to nursing mothers.⁶

Special populations: Elderly patients are at greater risk of developing severe toxicity when treated with the combination of leucovorin plus fluorouracil for the palliative treatment of colorectal cancer.² **Susceptible children** experience an increase in the frequency of seizures.²

SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.^{10,11} When placebo-controlled trials are available, adverse events are included if the incidence is $\geq 5\%$ higher in the treatment group.

ORGAN SITE	SIDE EFFECT	ONSET			
Clinically important side effects are in bold, italics I = immediate (onset in hours to days); E = early (days to weeks); D = delayed (weeks to months); L = late (months to years)					
allergy/immunology	allergic sensitization (<1%), including anaphylactoid reactions	I			
blood/bone marrow/ febrile neutropenia	in combination with fluorouracil: leucopenia (i.e., fluorouracil toxicity enhanced)	I			
constitutional symptoms	fatigue	I	E		
dermatology/skin	<i>extravasation hazard: none</i> ¹²				

ORGAN SITE	SIDE EFFECT	ONSET			
Clinically important side effects are in bold, italics I = immediate (onset in hours to days); E = early (days to weeks); D = delayed (weeks to months); L = late (months to years)					
	erythema, hives, rash, pruritus, urticaria ⁷	I	E		
gastrointestinal	<i>emetogenic potential: non-emetogenic</i>				
	in combination with fluorouracil: stomatitis, diarrhea (i.e., fluorouracil toxicity enhanced)	I	E		
neurology	seizures (<1%)	I			
pulmonary	wheezing ⁷	I			

Adapted from standard reference⁴ unless specified otherwise.

INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
capecitabine ⁷	increased cytotoxic and toxic effects of capecitabine	capecitabine is metabolized to fluorouracil; leucovorin stabilizes the bond to thymidylate synthetase	monitor toxicity
fluorouracil ²	increased cytotoxic and toxic effects of fluorouracil	leucovorin stabilizes the bond to thymidylate synthetase	some protocols are designed to take advantage of this effect; monitor toxicity closely
methotrexate	decreased toxicity of methotrexate	leucovorin "rescues" normal cells from toxic effects of methotrexate	administer leucovorin after methotrexate if required
phenobarbital ⁴	decreased efficacy of phenobarbital	unknown	primarily a concern with high doses of leucovorin; monitor for seizure control
phenytoin ^{4,13}	decreased efficacy of phenytoin	phenytoin requires folate for microsomal metabolism; leucovorin may interfere with this action	primarily a concern with high doses of leucovorin; monitor for seizure control
primidone ⁴	decreased efficacy of primidone	unknown	primarily a concern with high doses of leucovorin; monitor for seizure control
raltitrexed ¹⁴	decreased efficacy of raltitrexed	raltitrexed is a folate analogue that inhibits thymidylate synthetase; leucovorin may interfere with this action	do not coadminister raltitrexed and leucovorin
trimethoprim ^{2,15}	decreased efficacy of trimethoprim	unknown	if concomitant therapy is necessary, monitor for treatment efficacy

SUPPLY AND STORAGE:

Tablets: Wyeth supplies leucovorin as a 5 mg tablet.⁴ Selected non-medicinal ingredients: lactose. Store at room temperature and protect from light.

For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

SOLUTION PREPARATION AND COMPATIBILITY:

For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.

Compatibility of selected drugs¹⁶: The following are compatible with leucovorin via Y-site injection: filgrastim, furosemide, granisetron, heparin, metoclopramide, tacrolimus. The following are compatible with leucovorin in the same syringe at certain concentrations: fluorouracil, furosemide, heparin, metoclopramide.

Incompatibility of selected drugs²: The following are incompatible with leucovorin via Y-site injection: droperidol, fluorouracil, sodium bicarbonate. Leucovorin is incompatible in the same syringe with droperidol at certain concentrations.

Additional information¹⁶: Fluorouracil and leucovorin will precipitate at various concentrations and temperatures; they should not be considered compatible in the same container.

PARENTERAL ADMINISTRATION:

BCCA administration guideline noted in ***bold, italics***

Subcutaneous	no information found
Intramuscular	can be used ^{2†}
Direct intravenous	<i>by slow injection over a minimum of 3 min^{17*}</i>
Intermittent infusion	<i>in a suitable volume of compatible IV solution*</i>
Continuous infusion	no information found
Intraperitoneal	can be used ³
Intrapleural	no information found
Intrathecal	has been used; not recommended ^{2,17}
Intra-arterial	no information found
Intravesical	no information found

*rate not exceeding 160 mg/min due to calcium content¹⁶

†for doses >10mg/m² do not use diluents containing benzyl alcohol if reconstituting leucovorin from powder¹⁶

DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

Adults:BCCA usual dose noted in **bold, italics**Cycle
Length:


Leucovorin modulation of fluorouracil: 1-4 weeks¹⁸⁻²⁶: ***20 mg/m² IV for one dose on days 1-5***
(total dose per cycle 1000 mg/m²)

2 weeks²⁷⁻³⁰: ***400 mg/m² IV for one dose on day 1.***
(total dose per cycle 400 mg/m²)

Fluorouracil is usually given after, or at the midpoint of, a leucovorin infusion.¹⁷ Doses of leucovorin are not adjusted for toxicity but would be delayed or omitted if fluorouracil is delayed or omitted.⁶

Leucovorin rescue after methotrexate: **Leucovorin rescue³¹**: is required in some methotrexate regimens.
Methotrexate dose:

- >500 mg/m² requires leucovorin rescue.
- 100-500 mg/m² may require leucovorin rescue.



Reference: Bleyer WA. The clinical pharmacology of methotrexate – new applications of an old drug. *Cancer* 1978; 41: 36-51

Note: 0.05 µmol/L = 5 x 10⁻² micromoles/L

Leucovorin dose PO/IV/IM (see Bleyer nomogram):

- 10-25 mg/m² every 6 hours for approximately 8 to 10 doses, starting 24 hours after the start of methotrexate infusion.³¹⁻³⁶
- Leucovorin dose modifications begin on day 3, if required, based on methotrexate levels taken that morning (i.e., level taken 36-48 hours following the start of the methotrexate infusion). Methotrexate levels are repeated every morning and leucovorin adjusted based on the graph to follow.³²⁻³⁴

Continue until the methotrexate level is 0.05 µmol/L.^{31,37} Some clinicians use a range for the methotrexate level i.e., continue leucovorin until the methotrexate level is between 0.01-0.1 µmol/L.¹⁷

Notes:

- Leucovorin doses >25 mg should be given IV⁴
- If impaired elimination of methotrexate is suspected, monitor serum creatinine and methotrexate levels, and adjust the dose of leucovorin upwards according to the Bleyer nomogram.¹¹ See the Acute renal failure paragraph in the methotrexate monograph regarding the possible use of Carboxypeptidase-G2.

Concurrent radiation ^{20,21,25} :	can be used with variable schedules and dosing; specific treatment protocols must be consulted
Dosage in myelosuppression:	no adjustment required
Dosage in renal failure:	no adjustment required
Dosage in hepatic failure:	no adjustment required
Dosage in dialysis:	no information found

Children:

Leucovorin modulation of fluorouracil:	not indicated for colorectal cancer in pediatric patients ³¹
Leucovorin rescue after methotrexate*:	15 mg (10 mg/m ²) PO/IV/IM q6h starting 24 h after beginning of methotrexate infusion; continue until methotrexate level < 0.05µmol ³¹

*Methotrexate doses above 100 to 300 mg/m², which are usually administered by continuous infusion, must be followed by leucovorin rescue.³⁸

REFERENCES:

1. McEvoy G, editor. American Hospital Formulary Systems Drug Information. Bethesda, MD: American Society of Health System Pharmacists; 2006.
2. Mayne Pharma Canada Inc. Leucovorin Calcium Product Monograph. Montreal Quebec; 2003,.
3. Dorr RT, Von-Hoff DD. Cancer chemotherapy handbook. second ed. ed. Norwalk, Connecticut: Appleton & Lange; 1994. p. 624-30.
4. Wyeth Canada. Lederle Leucovorin Calcium Product Monograph. Montreal, Canada; 2004.
5. Jaffe N, Jorgensen K, Roberson R, et al. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma. Anticancer Drugs 1993;5:559.
6. Novopharm Limited. Leucovorin Calcium Product Monograph. Toronto, Canada; 1998,.
7. Micromedix. Leucovorin Calcium. In: DrugPoint Summary; 2006.

8. Widemann BC, Balis FM, Murphy RF, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. *Journal of Clinical Oncology* 1997;15(5):2125-34.
9. Briggs GG, Freeman RK, Yaffe SJ. *Drugs in Pregnancy and Lactation*. 5th ed. Baltimore: Williams & Wilkins; 1998.
10. Sharlene Gill, MD. Personal communication. Medical Oncologist BC Cancer Agency, Vancouver BC; June 2006.
11. Tamara Shenkier, MD. Personal communication. Medical Oncologist BC Cancer Agency, Vancouver BC; June 2006.
12. B.C. Cancer Agency Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and management of extravasation of chemotherapy. Vancouver, British Columbia: BC Cancer Agency; 1 February 2004.
13. Gilbar P, Brodribb T. Phenytoin and Fluorouracil Interaction. *The Annals of Pharmacotherapy* 2001;35:1367-70.
14. Lexi-Comp Inc. *Methotrexate/Bile Acid Sequestrants*; 2006.
15. Lexi-Comp Inc. *Trimethoprim/Leucovorin*; 2006.
16. Trissel L. *Handbook on injectable drugs*. 13th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2005.
17. Leucovorin Calcium. In: Thomson Scientific and Healthcare, editor. *Micromedex*; 2006.
18. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Adjuvant Therapy for Stage III and High Risk Stage II Colon Cancer using Leucovorin and Fluorouracil. Vancouver: BC Cancer Agency; GIFFAD, 2006.
19. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Advanced Colorectal Cancer using Leucovorin and Fluorouracil. Vancouver: BC Cancer Agency; GIFUFA, 2006.
20. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Fluorouracil, Leucovorin and Radiation Therapy. Vancouver: BC Cancer Agency; GIFUR, 2006.
21. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Combined Modality Adjuvant Therapy for Completely Resected Gastric Adenocarcinoma using Fluorouracil and Folinic Acid (Leucovorin) and Radiation Therapy. Vancouver: BC Cancer Agency; GIGAI, 2006.
22. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Palliative Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil and Folinic Acid (Leucovorin). Vancouver: BC Cancer Agency; UGIIRFUFA, 2006.
23. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Adjuvant Therapy for Resected Pancreatic Cancer using Leucovorin and Fluorouracil. Vancouver: BC Cancer Agency; GIPAJFF, 2006.
24. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Adjuvant Therapy for Stage II and III Rectal Cancer Previously Treated with Preoperative Radiation therapy. Vancouver: BC Cancer Agency; GIRFF, 2006.
25. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Pre-Operative Concurrent Chemotherapy and Radiotherapy and Post Operative Chemotherapy for Locally Advanced (Borderline Resectable or Unresectable) Rectal Adenocarcinoma (Interim Version). Vancouver: BC Cancer Agency; GIRLAIFF, 2006.
26. BC Cancer Agency Head and neck Tumour Group. BCCA Protocol summary for 5-Fluorouracil and Leucovorin for Recurrent Head and Neck Cancer. Vancouver: BC Cancer Agency; HNFUFA, 2001.
27. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil and Folic Acid (Leucovorin). Vancouver: BC Cancer Agency; GIFOLFIRI, 2006.
28. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Adjuvant Combination Chemotherapy for Stage III Colon Cancer using Oxaliplatin, 5-Fluorouracil and Folic Acid (Leucovorin). Vancouver: BC Cancer Agency; UGIAJFOLFOX, 2005.
29. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Irinotecan, Fluorouracil, Folic Acid (Leucovorin) and Bevacizumab. Vancouver: BC Cancer Agency; UGIFFIRB, 2006.
30. BC Cancer Agency Gastrointestinal Tumour Group. BCCA Protocol summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer using Oxaliplatin, 5-Fluorouracil and Folic Acid (Leucovorin). Vancouver: BC Cancer Agency; UGIFOLFOX, 2005.
31. Methotrexate: Drug Information. In: Rose BD, editor. *UpToDate*. Wellesley, MA,: UpToDate; 2006.
32. BC Cancer Agency Lymphoma Tumour Group. BCCA Protocol Summary for Treatment of Leptomeningeal Lymphoma with High Dose Methotrexate (LYHDMTXR). Vancouver: BC Cancer Agency; 2004.
33. BC Cancer Agency Lymphoma Tumour Group. BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate (LYHDMTXP). Vancouver: BC Cancer Agency; 2004.
34. BC Cancer Agency Lymphoma Tumour Group. BCCA Protocol Summary for Treatment of Burkitt Lymphoma with Cyclophosphamide and Methotrexate (LYSNCC). Vancouver: BC Cancer Agency; 2004.
35. BC Cancer Agency Gynecology Tumour Group. BCCA Protocol Summary for Low Risk Gestational Trophoblastic Cancer using Dactinomycin and Methotrexate (GOTDLR). Vancouver: BC Cancer Agency; 2003.
36. BC Cancer Agency Gynecology Tumour Group. BCCA Protocol Summary for High Risk Gestational Trophoblastic Cancer (GO9130) "MACE" using Cisplatin, Etoposide, Actinomycin D, Methotrexate, and Leucovorin (GOTDHR). Vancouver: BC Cancer Agency; 2005.
37. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. *Cancer* 1978;41(1):36-51.
38. Pizzo P, Poplack D. *Principles and Practice of Pediatric Oncology*. Fourth ed. Philadelphia: Lippincott Williams & Wilkins; 2002.